See more : Hologic Inc (HO1.DE) Income Statement Analysis – Financial Results
Complete financial analysis of NLS Pharmaceutics AG (NLSP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NLS Pharmaceutics AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Trada Alam Minera Tbk (TRAM.JK) Income Statement Analysis – Financial Results
- Britannia Bulk Holdings Inc. (BBLKF) Income Statement Analysis – Financial Results
- Terna Energy Societe Anonyme Commercial Technical Company (TREAY) Income Statement Analysis – Financial Results
- Analog Integrations Corporation (6291.TWO) Income Statement Analysis – Financial Results
- Senior Connect Acquisition Corp. I (SNRHU) Income Statement Analysis – Financial Results
NLS Pharmaceutics AG (NLSP)
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.41K | 11.41K | 10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -11.41K | -11.41K | -10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.91M | 8.98M | 5.92M | 99.58K | 1.70M | 1.44M | 4.32M |
| General & Administrative | 5.90M | 6.51K | 5.94K | 2.20K | 3.30M | 2.01M | 1.44M |
| Selling & Marketing | 0.00 | 6.49M | 5.93M | 2.20M | 2.49M | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 5.93M | 2.20M | 2.49M | 2.01M | 1.44M |
| Other Expenses | 0.00 | 10.05K | -17.32K | -328.37K | 0.00 | -629.23K | 0.00 |
| Operating Expenses | 11.81M | 15.47M | 11.85M | 2.30M | 4.20M | 3.45M | 5.77M |
| Cost & Expenses | 11.81M | 15.48M | 11.86M | 2.30M | 4.20M | 3.45M | 5.77M |
| Interest Income | 0.00 | 100.87 | 68.13 | 233.70 | 819.71 | 16.04K | 890.40 |
| Interest Expense | 145.15K | 100.87K | 68.13K | 233.70K | 819.71K | 1.07M | 890.40K |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 2.30M | 4.20M | 3.45M | 5.77M |
| EBITDA | -11.80M | -15.47M | -11.85M | 0.00 | -430.40K | -613.20K | -5.77M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.81M | -15.48M | -11.86M | -2.30M | -4.20M | -3.45M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -364.97K | -1.01M | -85.46K | -562.07K | -1.25M | -1.70M | -890.40K |
| Income Before Tax | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.00 | -226.51K | -2.30K | -4.20K | 1.70M | -5.77K |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Weighted Avg Shares Out | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
| Weighted Avg Shares Out (Dil) | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
NLS Pharmaceutics Announces Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple...
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice...
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock closed out Tuesday, the prior day of trading due to the Juneteenth...
Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?
NLS Pharmaceutics (NASDAQ: NLSP ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 73 million shares of the stock changing hands as of this writing.
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the...
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies. Medications activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders including...
Source: https://incomestatements.info
Category: Stock Reports